Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artivion Inc (AORT)

Artivion Inc (AORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call

5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call

AORT : 38.33 (+0.87%)
Artivion (AORT) Stock Trades Down, Here Is Why

Artivion (AORT) Stock Trades Down, Here Is Why

AORT : 38.33 (+0.87%)
AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline

AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline

AORT : 38.33 (+0.87%)
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations

Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations

AORT : 38.33 (+0.87%)
Artivion: Q4 Earnings Snapshot

Artivion: Q4 Earnings Snapshot

AORT : 38.33 (+0.87%)
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results

Fourth Quarter Highlights:

AORT : 38.33 (+0.87%)
What To Expect From Artivion’s (AORT) Q4 Earnings

What To Expect From Artivion’s (AORT) Q4 Earnings

AORT : 38.33 (+0.87%)
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity

AORT : 38.33 (+0.87%)
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results

ATLANTA , Jan. 29, 2026 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial...

AORT : 38.33 (+0.87%)
2 Stocks Under $50 to Research Further and 1 We Avoid

2 Stocks Under $50 to Research Further and 1 We Avoid

AMSC : 34.04 (+0.77%)
MIR : 21.28 (-0.88%)
AORT : 38.33 (+0.87%)

Barchart Exclusives

NVDA Earnings, Tariffs and Other Key Things to Watch this Week
Markets enter a critical week dominated by Wednesday's Nvidia earnings and escalating geopolitical tensions as rising U.S.-Iran hostilities push oil prices higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar